Kategorija: Pētniecība

Roche/ Genentech jaunākā informācija par pētījumu GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis izbeidz VIBRANT-HD pētījumu

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

uniQure paziņoja, ka atsāk pacientu uzņemšanu AMT-130 pētījumā ar lielākām devām.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences paziņo par pozitīviem jaunākajiem datiem 1.b/2a fāzes SELECT-HD pētījumā ar sākotnējiem rezultātiem, kas norāda uz alelas selektīvu mērķa iesaistīšanu ar WVE-003 Hantingtona slimības gadījumā

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure paziņo par jaunāko informāciju par AMT-130 gēnu terapijas Hantingtona slimības ārstēšanai I/II fāzes klīniskā pētījuma mazo devu kohortas atjauninājumu

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences atjaunina izmēģinājumu rezultātus

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinārs - Viss, kas jums jāzina par Proof-HD

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Pārsteidzošās ziņas - Roche plāno jaunu Tominersena pētījumu

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]